Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

BMC Cancer

Research Article

Rosana Peiro-Perez¹  M. Henar Alonso²  Víctor Moreno²  Beatriz Pérez-Gómez³  Virginia Lope³  Nuria Aragonés³  Marina Pollán³  Esther Gracia-Lavedan⁴  Manolis Kogevinas⁴  Gemma Castaño-Vinyals⁵  Adonina Tardon⁶  Marcela Guevara⁷  Pilar Amiano⁸  Trinidad Dierssen-Sotos⁹  Javier Llorca⁹  Inés Gómez-Acebo⁹  María de Pedro^1,10  Rafael Marcos-Gragera^1,11  Aurelio Barricarte^1,12  Maria Jesus Michelena-Echeveste^1,13  Andrés Garcia-Palomo^1,14  Sonia Servitja^1,15  Marian Diaz-Santos^1,16  Tania Fernandez-Villa^1,17 

[1] CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;Area de Cáncer y Salud Pública, Fundación FISABIO- Salud Pública, Valencia, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, and University of Barcelona, Barcelona, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain;Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain;Universitat Pompeu Fabra (UPF), Barcelona, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain;Universitat Pompeu Fabra (UPF), Barcelona, Spain;IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;IUOPA, Universidad de Oviedo, Oviedo, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;Navarra Public Health Institute, Pamplona, Spain;Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain;CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain;University of Cantabria – IDIVAL, Santander, Spain;Department of Obstetrics and Gynecology, Nuevo Belén University Hospital, Madrid, Spain;Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia and Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute (IdIBGi)], Catalan Institute of Oncology, Girona, Spain;Navarra Public Health Institute, Pamplona, Spain;Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;Onkologikoa- Oncology Institute Gipuzkoa, San Sebastian, Spain;Sección de Oncología, Complejo Asistencial Universitario de León, León, Spain;Servei d’Oncologia Mèdica, Hospital del Mar, Barcelona, Spain;Cancer Research Program IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain;Universidad de Huelva, Huelva, Spain;Centro de Investigación en Salud y Medio Ambiente (CYSMA), Huelva, Spain;Área de Medicina Preventiva y Salud Pública, Departamento de Ciencias Biomédicas, Universidad de León, León, España;Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Universidad de León, León, España;

关键词: Breast cancer;    Non-steroidal anti-inflammatory drug;    Hormone receptor positive breast cancer;    HER2 positive breast cancer;    Triple negative breast cancer;   

DOI  :  10.1186/s12885-016-2692-4

 received in 2015-12-01, accepted in 2016-08-09,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors).MethodsIn this case-control study, we report the NSAID – breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women’s characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics.ResultsIn our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64–0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers.ConclusionMost NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers.

【 授权许可】

CC BY   
© The Author(s). 2016